Research map: Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma

Back to the article

Papers in this map

  1. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial · Norbert Schmitz · 2002 · 1143 citations · Cited by this paper
  2. Recent advances in the pathophysiology and treatment of GVHD · 2026 · Related
  3. High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma · Thierry O. Philip · 1987 · 784 citations · Cited by this paper
  4. Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria · 2026 · Related
  5. Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents · Lorenzo M. Leoni · 2008 · 370 citations · Cited by this paper
  6. Current status and challenges of TCR-T cell therapy for AML/MDS · 2026 · Related
  7. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma · Patrick J. Stiff · 2013 · 346 citations · Cited by this paper
  8. T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel · 2026 · Related
  9. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. · Wendy Mills · 1995 · 294 citations · Cited by this paper
  10. NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives · 2026 · Related
  11. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients · Giuseppe Visani · 2011 · 139 citations · Cited by this paper
  12. Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan · 2026 · Related
  13. The systemic administration of intravenous melphalan. · Gisele Sarosy · 1988 · 125 citations · Cited by this paper
  14. Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms · 2026 · Related
  15. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation · Ulas D. Bayraktar · 2012 · 119 citations · Cited by this paper
  16. Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study · 2026 · Related
  17. A Review of Autologous Stem Cell Transplantation in Lymphoma · Umar Nazir Zahid · 2017 · 110 citations · Cited by this paper
  18. Zanubrutinib for MYD88-negative Waldenström’s macroglobulinemia with massive splenomegaly · 2026 · Related
  19. Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantation · Thierry O. Philip · 1991 · 89 citations · Cited by this paper
  20. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity · Jae‐Cheol Jo · 2008 · 87 citations · Cited by this paper
  21. Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia · NJ Chao · 1993 · 75 citations · Cited by this paper
  22. Peripheral T-Cell Non-Hodgkin's Lymphoma · Julie Marie Vose · 2008 · 57 citations · Cited by this paper
  23. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies · Partow Kebriaei · 2010 · 45 citations · Cited by this paper
  24. Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers · Sylvain Chantepie · 2018 · 44 citations · Cited by this paper
  25. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients · Stefanie Gilli · 2016 · 43 citations · Cited by this paper
  26. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites · Mona Darwish · 2015 · 37 citations · Cited by this paper
  27. Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma · Alison J. Moskowitz · 2019 · 35 citations · Cited by this paper
  28. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma · J G Kim · 2007 · 34 citations · Cited by this paper
  29. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies · Casey B. Williams · 2004 · 32 citations · Cited by this paper
  30. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma · Charles H. Weaver · 1998 · 31 citations · Cited by this paper
  31. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) · Liang Xu · 2018 · 31 citations · Cited by this paper
  32. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study · Alejandro Martı́n · 2022 · 30 citations · Cited by this paper
  33. Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial · On Behalf of the CISL · 2018 · 26 citations · Cited by this paper
  34. Controversies in the Treatment of Lymphoma with Autologous Transplantation · Alison J. Moskowitz · 2009 · 24 citations · Cited by this paper
  35. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma · Parastoo Bahrami Dahi · 2018 · 19 citations · Cited by this paper
  36. Stem cell transplantation for multiple myeloma: current and future status · Sergio A. Giralt · 2013 · 14 citations · Cited by this paper
  37. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma · Ho‐Jin Shin · 2014 · 12 citations · Cited by this paper
  38. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis · Ran Wu · 2023 · 12 citations · Cited by this paper
  39. Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma · Andrew Grigg · 2010 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)